Swedish medical technology company SciBase Holding AB (STO: SCIB) announced on Thursday that it has partnered with dermatology practice Seraly Dermatology in Pittsburgh, Pennsylvania.
Through this partnership SciBase will continue to expand access to the Nevisense test to patients across the US and further its commitment to the early detection of melanoma, when the disease is almost 100% curable.
Seraly Dermatology will integrate various Nevisense systems into its skin cancer detection workflow.
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial